Cover Image
市場調查報告書

第三型黏多糖症(MPSIII)(聖菲利柏氏症):開發平台分析

Mucopolysaccharidosis III - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 257789
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
第三型黏多糖症(MPSIII)(聖菲利柏氏症):開發平台分析 Mucopolysaccharidosis III - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 61 Pages
簡介

第三型黏多糖症(MPSIII)是以聖菲利柏氏症知名的遺傳性代謝疾病,是體內欠缺可分解葡萄糖胺聚糖 (glycosaminoglycans, GAG)分子所需的某種特定酵素或是功能不全造成的疾病。常見的症狀有中風、多動、肝臟或脾臟肥大、嚴重下痢或便祕、扁桃腺或咽喉扁桃腺肥大等。治療方法則包含了酵素補充療法(ERT)等。

本報告提供第三型黏多糖症(MPSIII)(聖菲利柏氏症)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

第三型黏多糖症(MPSIII)(聖菲利柏氏症)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Abeona Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc.
  • ArmaGen Inc.
  • Axcentua Pharmaceuticals AB
  • BioMarin Pharmaceutical Inc.
  • Dorphan S.A.
  • Laboratorios Del Dr. Esteve S.A.
  • Lysogene
  • Shire Plc
  • Swedish Orphan Biovitrum AB
  • UniQure N.V.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9432IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis III - Pipeline Review, H1 2017, provides an overview of the Mucopolysaccharidosis III (Metabolic Disorders) pipeline landscape.

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an inherited metabolic disease caused by an absence or malfunctioning of certain enzymes needed to breakdown molecules called glycosaminoglycans (GAG). Symptoms include seizures, hyperactivity, liver and spleen enlargement, severe diarrhea or constipation and enlargement of tonsils and adenoids. Treatment includes enzyme replacement therapy (ERT).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis III - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis III (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mucopolysaccharidosis III (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 6, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Mucopolysaccharidosis III (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis III (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis III (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mucopolysaccharidosis III (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mucopolysaccharidosis III (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis III (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis III (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis III (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Overview
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Companies Involved in Therapeutics Development
  • Abeona Therapeutics Inc
  • Alexion Pharmaceuticals Inc
  • ArmaGen Inc
  • Axcentua Pharmaceuticals AB
  • BioMarin Pharmaceutical Inc
  • Laboratorios Del Dr Esteve SA
  • Lysogene SAS
  • Swedish Orphan Biovitrum AB
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Drug Profiles
  • ABO-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABO-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AGT-184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AXP-10711 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMN-250 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EGT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EGT-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lesinidase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LYSSAF-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LYSSAF-302 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteins for Mucopolysaccharidosis Type IIIC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant N-Acetylgalactosamine-6-Sulfatase Replacement for Mucopolysaccharidosis Type IIID - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Sanfilippo Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SOBI-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Mucopolysaccharidosis Type IIIA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Sanfilippo Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy to Activate NAGLU for Mucopolysaccharidosis IIIB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Dormant Projects
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Discontinued Products
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
  • Oct 19, 2016: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA
  • May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)
  • Feb 25, 2016: ESTEVE Provides Update On EGT-201 For Sanfilippo B Syndrome
  • Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome
  • May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-101 From FDA
  • Apr 02, 2014: Orphan designation granted for MPSIII
  • Jul 25, 2013: New stem cell gene therapy gives hope to prevent inherited neurological disease
  • Apr 11, 2013: Axcentua granted patent on ten solid forms of genistein
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Abeona Therapeutics Inc, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by ArmaGen Inc, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Axcentua Pharmaceuticals AB, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Lysogene SAS, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Dormant Projects, H1 2017
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top